The Gastrointestinal Drugs market encompasses pharmaceutical products developed to treat conditions affecting the gastrointestinal (GI) tract, including the esophagus, stomach, intestines, liver, and pancreas. These drugs are aimed at managing and treating a range of GI disorders, such as acid reflux, irritable bowel syndrome (IBS), Crohn’s disease, ulcerative colitis, and various liver diseases. The market includes diverse drug classes such as antacids, proton pump inhibitors, laxatives, antidiarrheals, antiemetics, and biologics, all focused on alleviating symptoms, improving GI function, and enhancing patient quality of life.